Collaborative Research Consortia

CZECRIN (Czech Clinical Research Infrastructure Network) is the Czech national node of the pan-European ECRIN-ERIC research infrastructure, supporting non-commercial academic clinical trials across Czech hospitals and research institutions. It has actively showcased the PSIKET001 and PSIKET002 trials — landmark double-blind comparisons of psilocybin versus ketamine for treatment-resistant depression at the National Institute of Mental Health — as flagship examples of Czech psychedelic clinical innovation.

The Global Coalition for Adaptive Research (GCAR) is a US non-profit that serves as regulatory sponsor for adaptive platform trials, including GBM AGILE (glioblastoma) and the DOD-backed M-PACT (NCT05422612), which simultaneously evaluates multiple pharmacotherapies for PTSD in active-duty service members and veterans. GCAR modernizes drug development by replacing ineffective arms with new candidates within a single master protocol.

The National Network of Depression Centers (NNDC) is a US non-profit consortium of academic medical centres united to advance the prevention, diagnosis, and treatment of mood disorders through collaborative research, clinical programmes, and policy advocacy, with member institutions spanning more than 25 major academic health systems. The NNDC supported the BIO-K study, an open-label biomarker development trial investigating intravenous ketamine for non-psychotic unipolar major depression and bipolar I/II depression.

The Psychedelic Data Society is a US-based citizen-science nonprofit managing the Psychedelic Data Project, a global harm reduction and research initiative that collects participant-contributed data to accelerate psychedelic science and inform evidence-based drug policy reform.

Swiss medical society founded in 1985 whose members received special permission from the Swiss Federal Office of Public Health to conduct psychedelic-assisted therapy with MDMA and LSD in private practices from 1988 to 1993, treating approximately 170 patients. SÄPT continues to advance psycholytic therapy through research, training, and individual treatment licenses, and sponsored the LSD-Assist Study demonstrating persistent anxiety reductions at two-year follow-up.

A national nonprofit scientific society of healthcare professionals, researchers, and patient advocates dedicated to advancing pain research, education, and treatment in Canada. The Canadian Pain Society promotes the understanding and effective management of acute and chronic pain through scientific exchange, advocacy, and continuing education.

A nonprofit neuroimaging and neuroinformatics research organization based in Albuquerque, New Mexico, affiliated with the University of New Mexico. The Mind Research Network specializes in psychiatric and neurological brain imaging research using advanced MRI technologies, studying conditions including schizophrenia, addiction, PTSD, and traumatic brain injury.

Toronto's largest research hospital network and home to the Nikean Psychedelic Psychotherapy Research Centre — Canada's first dedicated psychedelic research centre, funded by a $5 million donation. Led by Dr. Emma Hapke, UHN's centre conducts psilocybin-assisted therapy trials for cancer patients and body dysmorphic disorder, alongside MDMA research for PTSD.